6-Bromonicotinic acid → (6-Bromopyridin-3-yl)[4-(5-ethyl-3-methylpyridin-2-yl)piperazin-1-yl]methanone

HRID 1804096노트

반응식

HRID 1804096 반응식
[Br:1][C:2]1[CH:10]=[CH:9][C:5]([C:6]([OH:8])=O)=[CH:4][N:3]=1.[CH2:11]([C:13]1[CH:14]=[C:15]([CH3:25])[C:16]([N:19]2[CH2:24][CH2:23][NH:22][CH2:21][CH2:20]2)=[N:17][CH:18]=1)[CH3:12]>>[Br:1][C:2]1[N:3]=[CH:4][C:5]([C:6]([N:22]2[CH2:23][CH2:24][N:19]([C:16]3[C:15]([CH3:25])=[CH:14][C:13]([CH2:11][CH3:12])=[CH:18][N:17]=3)[CH2:20][CH2:21]2)=[O:8])=[CH:9][CH:10]=1

참가 물질

3

실험 절차

By reaction and treatment in the same manner as in Preparation Example 27 and using 6-bromonicotinic acid (500 mg) and 1-(5-ethyl-3-methylpyridin-2-yl)piperazine (586 mg) described in Preparation Example 53, the title compound (530 mg) was obtained.

후처리

  1. customBy reaction and treatment in the same manner
  2. customas in Preparation Example 27
  3. customdescribed in Preparation Example 53

출처 및 근거

ORD 기록
ord-29e6667415b34ba8be974f50742ce8a3
출처 데이터셋
uspto-grants-2013_01
특허 번호
US08354401B2

반응 노트

불러오는 중…